FY2025 · period end Dec '25 · from the 10-K filed Feb 18, 2026
| Metric | FY25Dec '25 | FY24Dec '24 | FY23Dec '23 | FY22Dec '22 | FY21Dec '21 |
|---|---|---|---|---|---|
| Revenue | $4.02B |
Showing the most recent 5 annual periods. Get 15 years of history on the Pro plan, or unlimited history back to 1993 plus the smart-money dataset and webhooks on Institutional.
| Form | Accession ID | Report Date | Filing Date | Accepted At | Source |
|---|---|---|---|---|---|
| 8-K | 0000950103-26-007060 | May 5, 2026 | May 11, 2026 | May 11, 2026 21:01 UTC | EDGAR |
| 8-K | 0001100682-26-000036 | May 7, 2026 | May 7, 2026 | May 7, 2026 11:14 UTC | EDGAR |
| 10-Q | 0001100682-26-000038 | Mar 28, 2026 | May 7, 2026 | May 7, 2026 20:14 UTC | EDGAR |
| 8-K | 0001628280-26-011395 | Feb 25, 2026 | Feb 25, 2026 | Feb 25, 2026 12:34 UTC | EDGAR |
| 8-K | 0000950103-26-002326 | Feb 18, 2026 | Feb 18, 2026 | Feb 18, 2026 21:39 UTC | EDGAR |
| 8-K | 0001100682-26-000020 | Feb 18, 2026 | Feb 18, 2026 | Feb 18, 2026 12:13 UTC | EDGAR |
| 10-K | 0001100682-26-000022 | Dec 27, 2025 | Feb 18, 2026 | Feb 18, 2026 14:21 UTC | EDGAR |
| 8-K | 0001628280-26-001905 | Jan 13, 2026 | Jan 13, 2026 | Jan 13, 2026 13:10 UTC | EDGAR |
Direct links to SEC EDGAR. CRL has additional filings available on the SEC site.
Figures a later SEC filing revised from what was first reported. Each diff compares the same XBRL tag across two filings — both linked, so you can check it yourself.
Operating Income (Loss)·Q3 2010
Major restatementwas$5.1M
Revised up in a 10-Q.
Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest·Q3 2010
Major restatementwas-$8.9M
Revised up in a 10-Q.
Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest·Q2 2010
Notable restatementwas$20.6M
Revised up in a 10-Q.
Operating Income (Loss)·Q2 2010
Notable restatementwas$28.2M
Revised up in a 10-Q.
Revenue, Net (Deprecated 2018-01-31)·Q3 2010
Minor restatementwas$276.1M
Revised down in a 10-Q. Any P/S built on the original was 1.9% too low.
Long-term Debt, Gross·As of Dec 30, 2017
Minor restatementwas$1.1B
Revised up in a 10-Q.
CRL is not the only one.
See every restatement we've found across the market — or get an alert the next time CRL revises a number.
Restatements are detected by comparing every vintage of a fact across all of CHARLES RIVER LABORATORIES INTERNATIONAL, INC.'s filings back to 1993. A revision is not by itself a sign of wrongdoing — companies re-file for many legitimate reasons. This list is not exhaustive: it shows CRL's most significant revisions, and a figure absent from it has not been certified as unrevised.
Who is buying and selling CHARLES RIVER LABORATORIES INTERNATIONAL, INC. — insider transactions from Forms 3/4/5/144 and institutional ownership from 13F, 13D, and 13G filings, point-in-time stamped like every other fact in the library. Traders read it as a positioning signal; risk desks read it as concentration.
No published research on CRL yet.
Reports appear here as analysts publish research on this company — built with Valuein's agentic workflows, every figure pinned to its SEC filing. Be the first: run equity_research_brief on CRL and publish the result to your public profile.
Get 15 years of data
Quarterly and annual financials back to 2011 on Pro (1993 on Institutional). Point-in-time accurate with zero survivorship bias.
View plansQuery via Python SDK
Pull data into DuckDB with 3 lines of Python. Works in Jupyter notebooks, scripts, and CI pipelines.
SDK docsConnect via MCP Server
Wire Claude, Cursor, or Codex directly to live SEC data with a single Bearer token. No scraping, no glue code.
MCP docs| $4.13B |
| $3.98B |
| $3.54B |
| Gross Profit | — | — | — | — | — |
|---|
| Operating Income | $0.03B | $0.23B | $0.62B | $0.65B | $0.59B |
|---|
| Net Income | negative: -$0.14B | $0.02B | $0.47B | $0.49B | $0.39B |
|---|
| EPS (Diluted) | negative: -$2.91 | $0.20 | $9.22 | $9.48 | $7.60 |
|---|
| Metric | FY25Dec '25 | FY24Dec '24 | FY23Dec '23 | FY22Dec '22 | FY21Dec '21 |
|---|---|---|---|---|---|
| Total Assets | $7.14B | $7.53B | $8.20B | $7.60B | $7.02B |
| Total Liabilities | $3.92B | $4.02B | $4.54B | $4.58B | $4.43B |
| Stockholders' Equity | $3.17B | $3.47B | $3.60B | $2.98B | $2.54B |
| Cash & Equivalents | $0.21B | $0.21B | $0.28B | $0.24B | $0.25B |
| Total Debt | $2.14B | $2.24B | $2.65B | $2.71B | $2.66B |
| Metric | FY25Dec '25 | FY24Dec '24 | FY23Dec '23 | FY22Dec '22 | FY21Dec '21 |
|---|---|---|---|---|---|
| Operating Cash Flow | $0.74B | $0.73B | $0.68B | $0.62B | $0.76B |
| Capital Expenditures | — | — | — | — | — |
| Free Cash Flow | — | — | — | — | — |
| Metric | FY25Dec '25 | FY24Dec '24 | FY23Dec '23 | FY22Dec '22 | FY21Dec '21 |
|---|---|---|---|---|---|
| Gross Margin | — | — | — | — | — |
| Operating Margin | 0.6% | 0.1% | 0.1% | 0.2% | 0.2% |
| Net Margin | negative: -3.6% | 0.0% | 0.1% | 0.1% | 0.1% |
| Return on Equity | negative: -4.6% | 0.6% | 14.4% | 16.3% | 16.8% |
| Return on Assets | negative: -2.0% | 0.3% | 6.0% | 6.4% | 6.2% |
| Debt / Equity | 0.67× | 0.61× | 0.73× | 0.91× | 1.05× |
